$MCK · MCKESSON CORP
McKesson filed its 10-Q for the quarter ended September 30, 2026. Revenues grew 8% YoY to $110.96B, gross profit rose 12% to $3.96B, and net income attributable to McKesson increased 10% to $1.22B. Diluted EPS rose 17% to $10.44, aided by a 6% reduction in weighted-average diluted shares to 116.7M. Six-month net income attributable to McKesson fell 3% to $1.83B, driven by a $496M noncontrolling-interest charge versus $100M a year earlier.
- Q2 revenue $110.96B, up 8% YoY from $103.15B.
- Diluted EPS $10.44, up 17% from $8.92.
- Gross margin improved 14 bps to 3.57%.
- Six-month net income attributable to McKesson fell 3% to $1.83B on a $496M noncontrolling-interest charge.
- Company repurchased $3.42B of common stock in the six-month period.
Extended-hours last trade $1,056.00, down 1.15% from the $1,068.31 regular close, despite the EPS beat — a modest fade after a +6.87% regular-session gain.
A 17% EPS jump on 8% revenue growth and aggressive buybacks shows strong operating leverage, though a large noncontrolling-interest charge trimmed six-month attributable profit.
North American Pharmaceutical segment revenue rose to $91.36B, with Oncology & Multispecialty up 24% to $14.98B, reflecting continued drug-utilization growth across the distribution peer group.
Regulatory and drug-pricing risk, including 340B program developments, could alter pharmaceutical supply-chain economics. Rising interest expense and the large noncontrolling-interest charge weigh on consolidated net income.